Condition: Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Acute · Multiple Myeloma · Sponsor: Sumitomo Pharma America, Inc.
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
This description comes directly from the study's public registry record.
Matt Hitron, MD · 508-481-6700 · matthew.hitron@us.sumitomo-pharma.com
Tomoko Kuwabara · tomoko.kuwabara@us.sumitomo-pharma.com
Always discuss trial participation with your own doctor first.
| Hoag Family Cancer Center | Newport Beach, California, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Not Yet Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Georgetown Lombardi Comprehensive Cancer Center | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Miami Cancer Institute | Miami, Florida, United States | Not Yet Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Not Yet Recruiting |
| Northwestern | Chicago, Illinois, United States | Recruiting |
| Sibley Memorial Hospital | Baltimore, Maryland, United States | Recruiting |
| University of Maryland | Baltimore, Maryland, United States | Recruiting |
| Johns Hopkins Main Center | Baltimore, Maryland, United States | Recruiting |
| Tufts University | Boston, Massachusetts, United States | Withdrawn |
+ 92 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04988555